600613.SS
Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600613.SS Stock Summary
Top 10 Correlated Stocks
600613.SS
In the News
600613.SS Financial details
Company Rating
Buy
Market Cap
3.31B
Income
57.03M
Revenue
2.39B
Book val./share
4.77
Cash/share
1.48
Dividend
0.1
Dividend %
1.38%
Employees
1.57K
Optionable
No
Shortable
Yes
Earnings
30 Apr 2021
P/E
62.41
Forward P/E
-
PEG
-32.85
P/S
1.56
P/B
1.52
P/C
4
P/FCF
-2209.38
Quick Ratio
2.32
Current Ratio
2.75
Debt / Equity
0.12
LT Debt / Equity
0.09
-
-
EPS (TTM)
0.11
EPS next Y
-
EPS next Q
-
EPS this Y
-30.77%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-14.76%
Revenue last 5Y
5.21%
Revenue Q/Q
-18.95%
EPS Q/Q
245.65%
-
-
-
-
SMA20
-14.29%
SMA50
-14.29%
SMA100
-25%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
2%
ROC
0.03%
Gross Margin
50%
Oper. Margin
3%
Profit Margin
2%
Payout
116%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.65-9.31
52W High
-34.22%
52W Low
+48%
RSI
42
Rel Volume
0.76
Avg Volume
8.67M
Volume
6.58M
Perf Week
-11.11%
Perf Month
-6.33%
Perf Quarter
-23.32%
Perf Half Y
-28.85%
-
-
-
-
Beta
0.608
-
-
Volatility
0.31%, 0.26%
Prev Close
-2.79%
Price
5.92
Change
4.23%
600613.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.49 | 3.67 | 3.41 | 4.31 | 4.47 | |
| Net income per share | 0.2 | 0.16 | -0.66 | 0.13 | 0.09 | |
| Operating cash flow per share | 0.28 | 0.24 | 0.19 | 0.35 | 0.6 | |
| Free cash flow per share | 0.07 | 0.1 | 0.01 | 0.18 | 0.55 | |
| Cash per share | 0.57 | 1.12 | 0.88 | 0.9 | 1.21 | |
| Book value per share | 4.79 | 4.99 | 4.27 | 4.39 | 4.36 | |
| Tangible book value per share | 3.79 | 3.97 | 3.6 | 3.72 | 3.7 | |
| Share holders equity per share | 4.79 | 4.99 | 4.27 | 4.39 | 4.36 | |
| Interest debt per share | 0.09 | 0.78 | 0.65 | 0.6 | 0.57 | |
| Market cap | 2.55B | 3.79B | 2.61B | 3.43B | 4.4B | |
| Enterprise value | 2.37B | 3.6B | 2.47B | 3.25B | 4.02B | |
| P/E ratio | 24.05 | 45.13 | -7.39 | 49.25 | 90.67 | |
| Price to sales ratio | 1.38 | 1.97 | 1.44 | 1.49 | 1.84 | |
| POCF ratio | 17.18 | 29.54 | 26.36 | 18.61 | 13.77 | |
| PFCF ratio | 66.65 | 73.84 | 935.91 | 34.88 | 15.02 | |
| P/B Ratio | 1 | 1.45 | 1.15 | 1.46 | 1.89 | |
| PTB ratio | 1 | 1.45 | 1.15 | 1.46 | 1.89 | |
| EV to sales | 1.28 | 1.87 | 1.36 | 1.41 | 1.68 | |
| Enterprise value over EBITDA | 12.04 | 14.26 | 39.71 | 18.28 | 19.93 | |
| EV to operating cash flow | 15.98 | 28.03 | 24.97 | 17.62 | 12.61 | |
| EV to free cash flow | 61.98 | 70.08 | 886.51 | 33.03 | 13.75 | |
| Earnings yield | 0.04 | 0.02 | -0.14 | 0.02 | 0.01 | |
| Free cash flow yield | 0.02 | 0.01 | 0 | 0.03 | 0.07 | |
| Debt to equity | 0.01 | 0.15 | 0.15 | 0.13 | 0.12 | |
| Debt to assets | 0.01 | 0.11 | 0.11 | 0.1 | 0.08 | |
| Net debt to EBITDA | -0.91 | -0.77 | -2.21 | -1.02 | -1.84 | |
| Current ratio | 3.57 | 3.22 | 3.13 | 3.01 | 2.29 | |
| Interest coverage | 12.24 | 21.59 | 1.91 | 12.15 | 6.07 | |
| Income quality | 1.51 | 1.59 | -0.28 | 2.71 | 6.65 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0.02 | |
| Payout ratio | 0.21 | 0.05 | -0.02 | 0.06 | 1.42 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Intangibles to total assets | 0.19 | 0.16 | 0.13 | 0.13 | 0.12 | |
| Capex to operating cash flow | -0.74 | -0.6 | -0.97 | -0.47 | -0.08 | |
| Capex to revenue | -0.06 | -0.04 | -0.05 | -0.04 | -0.01 | |
| Capex to depreciation | -2.32 | -1.39 | -1.82 | -1.3 | -0.28 | |
| Stock based compensation to revenue | 0 | 0.01 | 0.01 | 0 | 0 | |
| Graham number | 4.64 | 4.24 | 7.98 | 3.59 | 2.98 | |
| ROIC | 0.04 | 0.05 | 0 | 0.03 | 0.03 | |
| Return on tangible assets | 0.04 | 0.03 | -0.13 | 0.03 | 0.02 | |
| Graham Net | 1.64 | 1.13 | 0.63 | 0.7 | 0.77 | |
| Working capital | 1.25B | 1.3B | 973.89M | 966.05M | 995.55M | |
| Tangible asset value | 2.01B | 2.08B | 1.92B | 1.99B | 1.98B | |
| Net current asset value | 1.21B | 984.41M | 661.01M | 689.4M | 761.98M | |
| Invested capital | 0.01 | 0.15 | 0.15 | 0.13 | 0.12 | |
| Average receivables | 1.33B | 1.22B | 904.32M | 721.59M | 807.22M | |
| Average payables | 160.64M | 172.42M | 157.09M | 169.53M | 187.56M | |
| Average inventory | 191.55M | 168.02M | 182.32M | 204.42M | 211.98M | |
| Days sales outstanding | 264.79 | 206.81 | 143.76 | 115.18 | 135.65 | |
| Days payables outstanding | 91.49 | 84.03 | 74.84 | 74.98 | 60.61 | |
| Days of inventory on hand | 88.31 | 82.75 | 101.12 | 81.68 | 71 | |
| Receivables turnover | 1.38 | 1.76 | 2.54 | 3.17 | 2.69 | |
| Payables turnover | 3.99 | 4.34 | 4.88 | 4.87 | 6.02 | |
| Inventory turnover | 4.13 | 4.41 | 3.61 | 4.47 | 5.14 | |
| ROE | 0.04 | 0.03 | -0.16 | 0.03 | 0.02 | |
| Capex per share | -0.21 | -0.15 | -0.18 | -0.16 | -0.05 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.87 | 1.27 | 0.98 | 1.05 | 1.03 | |
| Net income per share | 0.04 | -0.02 | 0.04 | 0.02 | 0.06 | |
| Operating cash flow per share | 0.04 | -0.02 | 0.04 | 0.2 | 0.05 | |
| Free cash flow per share | 0.03 | -0.03 | 0.03 | 0.19 | 0.04 | |
| Cash per share | 1.06 | 1.21 | 1.12 | 1.24 | 1.48 | |
| Book value per share | 3.98 | 4.36 | 3.96 | 3.89 | 4.77 | |
| Tangible book value per share | 3.38 | 3.7 | 3.37 | 3.31 | 4.07 | |
| Share holders equity per share | 3.98 | 4.36 | 3.96 | 3.89 | 4.77 | |
| Interest debt per share | 0.5 | 0.54 | 0.49 | 0.46 | 0.56 | |
| Market cap | 3.04B | 4.4B | 4.5B | 4B | 3.8B | |
| Enterprise value | 2.7B | 4.02B | 4.14B | 3.55B | 3.37B | |
| P/E ratio | 32.43 | -123.14 | 47.31 | 91.3 | 30.47 | |
| Price to sales ratio | 5.96 | 6.5 | 7.73 | 6.42 | 7.53 | |
| POCF ratio | 129.71 | -492.57 | 189.25 | 33.62 | 164.36 | |
| PFCF ratio | 190.37 | -301.83 | 222.81 | 34.81 | 191.53 | |
| P/B Ratio | 1.3 | 1.89 | 1.91 | 1.73 | 1.62 | |
| PTB ratio | 1.3 | 1.89 | 1.91 | 1.73 | 1.62 | |
| EV to sales | 5.29 | 5.96 | 7.1 | 5.7 | 6.67 | |
| Enterprise value over EBITDA | 60.08 | 1.18K | 109.24 | 118.09 | 102.27 | |
| EV to operating cash flow | 115.12 | -451.01 | 174.04 | 29.86 | 145.5 | |
| EV to free cash flow | 168.95 | -276.36 | 204.91 | 30.91 | 169.54 | |
| Earnings yield | 0.01 | 0 | 0.01 | 0 | 0.01 | |
| Free cash flow yield | 0.01 | 0 | 0 | 0.03 | 0.01 | |
| Debt to equity | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |
| Debt to assets | 0.09 | 0.08 | 0.09 | 0.08 | 0.08 | |
| Net debt to EBITDA | -7.62 | -109.11 | -9.55 | -14.87 | -13.26 | |
| Current ratio | 2.72 | 2.29 | 2.91 | 2.48 | 2.75 | |
| Interest coverage | 11.18 | -2.04 | 6.42 | 7.81 | 9.67 | |
| Income quality | 1 | 1 | 1 | 10.86 | 0.74 | |
| Dividend Yield | 0.02 | 0 | 0 | 0.01 | 0.01 | |
| Payout ratio | 2.48 | -0.23 | 0.14 | 2.82 | 0.95 | |
| Sales general and administrative to revenue | 0.11 | -0.06 | 0.03 | -0.01 | 0.1 | |
| Research and developement to revenue | 0.04 | 0.01 | 0.03 | 0 | 0.02 | |
| Intangibles to total assets | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |
| Capex to operating cash flow | -0.32 | 0.63 | -0.15 | -0.03 | -0.14 | |
| Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Capex to depreciation | -0.31 | -0.23 | -0.15 | -0.17 | 0.07 | |
| Stock based compensation to revenue | -0.02 | -0.06 | 0 | 0 | 0 | |
| Graham number | 1.89 | 1.28 | 1.89 | 1.27 | 2.61 | |
| ROIC | 0.01 | 0 | 0.01 | 0 | 0.01 | |
| Return on tangible assets | 0.01 | 0 | 0.01 | 0 | 0.01 | |
| Graham Net | 0.75 | 0.77 | 0.88 | 0.81 | 1.08 | |
| Working capital | 1B | 995.55M | 1.04B | 1B | 1.05B | |
| Tangible asset value | 1.98B | 1.98B | 2B | 1.97B | 2B | |
| Net current asset value | 753.16M | 761.98M | 804.04M | 777.42M | 827.15M | |
| Invested capital | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |
| Average receivables | 729.42M | 797.17M | 797.57M | 708.81M | 686.48M | |
| Average payables | 191.02M | 193.27M | 194.21M | 219.02M | 235.75M | |
| Average inventory | 242.91M | 230.23M | 210.51M | 214.11M | 238.88M | |
| Days sales outstanding | 124.56 | 118.22 | 109.25 | 102.61 | 118.15 | |
| Days payables outstanding | 89.27 | 46.13 | 67.24 | 71.25 | 82.48 | |
| Days of inventory on hand | 107.99 | 54.04 | 67.43 | 68.12 | 88.32 | |
| Receivables turnover | 0.72 | 0.76 | 0.82 | 0.88 | 0.76 | |
| Payables turnover | 1.01 | 1.95 | 1.34 | 1.26 | 1.09 | |
| Inventory turnover | 0.83 | 1.67 | 1.33 | 1.32 | 1.02 | |
| ROE | 0.01 | 0 | 0.01 | 0 | 0.01 | |
| Capex per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
600613.SS Frequently Asked Questions
What is Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. stock symbol ?
Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. is a CN stock and trading under the symbol 600613.SS
What is Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. stock quote today ?
Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. stock price is $5.92 today.
Is Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. stock public?
Yes, Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 8.67M
- Market Capitalization 3.31B
- Employee 1.57K
- CEO Mr. Feng Bin
- Headquarters Shanghai,CN
- IPO Date 1992-08-20
-
Website
https://www.gzsq.com 
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, tonic products, cold and cough, children's medicine, and anti-fungal drugs. Its products include prescription drugs and OTC products. The company was founded in 1992 and is based in Shanghai, China.
